|
|
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
|
|
|
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
|
|
|
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
|
|
|
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
|
|
|
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
|
|
|
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
|
|
|
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
|
|
|
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
|
|
|
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
|
|
|
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
|
